Apogee Therapeutics Inc. (APGE)
Apogee Therapeutics Inc. (APGE) Stock Price, Analysis & Data
| Bid | 96.59 |
| Market Cap | 10.18B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -294.37M |
| Beta | 0.34 |
| EPS (ttm) | -4.35 |
| PE Ratio (ttm) | n/a |
| Forward PE | -25.71 |
| P/B (ttm) | 10.18 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 9, 2026 |
| Ask | 171.87 |
| Volume | 1,479,779 |
| Avg. Volume (20D) | 2,734,806 |
| Open | 134.45 |
| Previous Close | 134.45 |
| Day's Range | 134.45 - 134.58 |
| 52-Week Range | 35.39 - 134.88 |
| Analyst | Hold |
| Price Target | 135 (0.33%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About APGE
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clin...
Financial Performance
In 2025, Apogee Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -255.84M, an increase of 40.46%.
Financial StatementsAnalyst Forecast
According to 11 analyst ratings, the average rating for APGE stock is "Hold". The 12-month stock price forecast is 135, which is upside of 0.33% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
